Latest news with #Sitagliptin
The Hindu
a day ago
- Business
- The Hindu
Abbott to distribute MSD's diabetes drug in India
Abbott and MSD Pharmaceuticals have entered into a distribution agreement for MSD's oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version in India. Leveraging its broad footprint in the country Abbott will distribute the portfolio. The products are marketed under brand names Januvia, Janumet and Janumet XR, the companies said in a joint statement. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitors used for treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity, they said. 'Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health,' V-P of Abbott in India Ambati Venu said. MSD India Region Managing Director Rehan A. Khan said, 'Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
Hans India
a day ago
- Health
- Hans India
Abbott and MSD Announce Strategic Partnership to Distribute Innovative Oral Anti-Diabetic Medicines in India
Abbott and MSD Pharmaceuticals (tradename of Merck & Co., Inc., Rahway, N.J., USA) are announcing a strategic collaboration through a distribution agreement for MSD's oral anti-diabetic medicine, Sitagliptin, its combination, Sitagliptin/Metformin, and the extended-release version in India. Under this agreement, Abbott will distribute this portfolio, leveraging its broad in-country footprint to continue to make these medicines available to people in India. MSD's Sitagliptin, its combination, and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Sitagliptin is a DPP4i or Dipeptidyl Peptidase IV Inhibitor, used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after loss of exclusivity. In India, at least 60 per cent of deaths are attributed to non-communicable diseases or NCDs. Amongst these, the leading causes are diabetes, cardiovascular conditions and cancer. The country has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future. 'As the largest diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system,' said Ambati Venu, Vice President for Abbott in India. He further added, 'We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health.' Rehan A. Khan, Managing Director, MSD India Region stated, 'Since its introduction in India over 17 years ago, our sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments.'
Economic Times
a day ago
- Health
- Economic Times
Abbott, MSD Pharmaceuticals ink distribution pact for oral anti-diabetic medicines in India
IANS Oral anti-diabetic medicines (Representational Image) Abbott and MSD Pharmaceuticals on Wednesday announced a partnership for distribution of oral anti-diabetic medicines in India. Under a distribution agreement, Abbott will distribute the oral anti-diabetic medicine sitagliptin, its combination sitagliptin/metformin and the extended-release version of MSD Pharmaceuticals (MSD) in India, the two companies said in a joint statement. MSD's sitagliptin, its combination and extended-release versions are marketed under the brand names Januvia, Janumet and Janumet XR. Abbott will leverage its broad in-country footprint to continue to make these medicines available to people in India, the statement said. MSD India Region Managing Director, Rehan A Khan, said that since its introduction in India over 17 years ago, the sitagliptin portfolio has positively impacted the lives of hundreds of thousands of patients across the country and has earned the trust of both doctors and patients. "Our partnership with Abbott establishes a sustainable business model that will enable us to continue to serve patients throughout India with these diabetes treatments," he added. India has an estimated 101 million people with diabetes, and 136 million people who are pre-diabetic, and are at a higher risk of developing diabetes in the future, the statement said. Being a large diversified healthcare company in India, Abbott is uniquely positioned to address some of the most pressing health challenges, particularly non-communicable diseases, which contribute to a considerable burden on the healthcare system, Ambati Venu, vice president for Abbott in India, said. "We offer a wide range of solutions to help people manage diabetes more effectively, including testing, continuous glucose monitoring, nutrition and a complete diabetes medicines portfolio. Through our extensive presence, we can help people in India better manage their Type 2 diabetes and take control of their health," he added. Sitagliptin is a Dipeptidyl Peptidase IV Inhibitor (DPP4i) used for the treatment of Type 2 diabetes. It was discovered and developed by MSD Pharmaceuticals and was the first DPP4i to be launched in India in 2008. The brands under this portfolio continue to be among the leaders in the category, even after the loss of exclusivity, the statement said.
